Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

Jeff P. Sharman, Andres Forero-Torres, Luciano J. Costa, Ian W. Flinn, Lowell Inhorn, Kevin Kelly, Alberto Bessudo, Luis E. Fayad, Mark S. Kaminski, Andrew M. Evens, Christopher R. Flowers, Deniz Sahin, Kirsten E. Mundt, Thomas Sandmann, Günter Fingerle-Rowson, Charlotte Vignal, Mehrdad Mobasher, Andrew D. Zelenetz

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) on patient outcomes. Patients (N = 100) received obinutuzumab (1000 mg on the days 1, 8, and 15 of cycle 1, and day 1 of cycles 2–8) plus CHOP (cycles 1–6). For patients without grade ≥3 infusion-related reactions (IRRs) to standard-rate obinutuzumab infusion, a shorter duration of infusion (SDI) was evaluated. Overall and complete response rates, as determined according to the Cheson et al. criteria by investigators/independent radiological facility, were 82.0/75.0% and 55.0/58.0%, respectively. SDI of 120 minutes and 90 minutes were well tolerated with no grade ≥3 IRRs. Among all patients, IRRs typically occurred during cycle 1, day 1. G-CHOP is active and has an acceptable safety profile in the first-line treatment of patients with advanced DLBCL. Clinical Trials: NCT01414855DLBCL.

Original languageEnglish (US)
Pages (from-to)894-903
Number of pages10
JournalLeukemia and Lymphoma
Volume60
Issue number4
DOIs
StatePublished - Mar 21 2019

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Keywords

  • Efficacy
  • obinutuzumab
  • safety profile

Fingerprint

Dive into the research topics of 'Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study'. Together they form a unique fingerprint.

Cite this